News and Trends 30 Sep 2022 Treatment for hot flushes and night sweats accepted for regulatory review by EMA A treatment for moderate to severe vasomotor symptoms (VMS) has been accepted by the European Medicines Agency (EMA) for regulatory review. Astellas Pharma Inc., submitted a marketing authorization application (MAA) for fezolinetant, an investigational oral, nonhormonal compound. VMS is characterized by hot flushes and/or night sweats which are common menopausal symptoms. Hot flushes The news […] September 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2022Beyond Biotech podcast 16: Adocia, Omnio, Phenomix Sciences, Tridek-One This week, we have four guests: Olivier Soula, deputy-CEO and director of R&D at Adocia; Ulrika Norin, CEO of Omnio; Mark Bagnall, CEO of Phenomix Sciences; and Laurence de Schoulepnikoff, CEO of Tridek-One. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. This week’s podcast is sponsored […] September 30, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Kling Biotherapeutics doses first patient in advanced solid tumor trial Kling Biotherapeutics BV has dosed the first patient with KBA1412 in its phase 1b trial to evaluate the safety, tolerability, PK/PD, and potential efficacy of KBA1412 in adult patients with advanced solid tumors not responding to standard of care. KBA1412 is a first in class fully human anti-CD9 antibody based on an antibody produced by […] September 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 European Science Park Group creates specialized space for innovative industries ESPG AG – European Science Park Group – is one of the first German real estate companies to specialize in the ownership, management and acquisition of science parks. A science park is a concept that originated in the U.S. and has already developed into its own asset class in the U.K. and other European countries. […] September 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Umeå Biotech Incubator launches international coaching program The Umeå Biotech Incubator (UBI) in Sweden specializes in developing life science business ideas. Now it is launching an international incubator program. “If you strive to be one of the world’s best incubators you must have the whole world as your marketplace,” said Jennie Ekbeck, CEO of Umeå Biotech Incubator. Umeå Biotech Incubator was founded […] September 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 NeuShen Therapeutics closes $20M pre-A financing Chinese biotech company NeuShen Therapeutics, Inc. has closed an approximately $20 million series pre-A financing led by LAPAM, a China based venture capital. The new capital will be used to expand the team and catalyze in-house CNS (central nervous system) drug discovery in both the U.S. and China. “The successful completion of this fundraising is […] September 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 29 Sep 2022 Removing binding sites for an oncogene can slow cancer cell growth, researchers say Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers from the University of Helsinki have discovered. They have found a mechanism by which an oncogene commonly activated in cancer patients affects the growth rate of cells. In the future, the findings can help in developing new treatments that could […] September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Positive results from study of drug to treat patients with breast cancer published Results from a phase 1b study of a drug to treat patients with androgen receptor positive (AR+) metastatic breast cancer (mBC) in China were published yesterday (September 28). Kintor Pharmaceutical Limited, a clinical stage biotech company has developed Pruxelutamide, an oral new generation AR antagonist which has shown promising activity in heavily pretreated AR+ mBC […] September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Startup Scout 29 Sep 2022 Baseimmune makes future-proof vaccines with AI Baseimmune is using artificial intelligence (AI) to design vaccines that can protect against future variants of infectious diseases including COVID-19 and malaria. Big data has taken off in the last decade, with dramatic improvements in bioinformatics, data science and AI. These advances allow researchers to store and handle more and more data generated by research […] September 29, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Treatment for adults with chronic skin condition approved by FDA The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases […] September 29, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Human cells can now help scientists accelerate cure for neurodegenerative diseases Cell products providing a scalable source of human cells can now help scientists study neurogenerative diseases in human context. UK-based, cell-coding company, bit.bio announced the expansion to its portfolio today (September 29) with disease model, ioGlutamatergic Neurons TDP-43 and early access to its ioMicroaglia cell product. Despite research efforts and funding, bit.bio says the development […] September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 29 Sep 2022 Positive results from Eisai and Biogen Alzheimer’s trial Eisai Co., Ltd. and Biogen Inc. have announced positive topline results from Eisai’s large global phase 3 confirmatory Clarity AD clinical trial of lecanemab to treat mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. Lecanemab is an […] September 29, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email